Y-mAbs Therapeutics, Inc. Quarterly Liabilities, Current in USD from Q4 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Summary
Y-mAbs Therapeutics, Inc. quarterly Liabilities, Current history and growth rate from Q4 2017 to Q3 2024.
  • Y-mAbs Therapeutics, Inc. Liabilities, Current for the quarter ending September 30, 2024 was $25.3M, a 16% increase year-over-year.
Liabilities, Current, Quarterly (USD)
Liabilities, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $25.3M +$3.48M +16% Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $43.5M +$19.2M +79.4% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $17.6M -$8.32M -32.1% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $20.1M -$8.16M -28.8% Dec 31, 2023 10-Q 2024-11-08
Q3 2023 $21.8M -$10.2M -31.9% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $24.2M -$5.22M -17.7% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $25.9M -$3.12M -10.8% Mar 31, 2023 10-Q 2023-05-08
Q4 2022 $28.3M +$409K +1.47% Dec 31, 2022 10-K 2024-02-29
Q3 2022 $32M +$6.66M +26.2% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $29.5M +$8.46M +40.3% Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $29M +$12M +70.8% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $27.9M +$8.34M +42.7% Dec 31, 2021 10-K 2023-03-30
Q3 2021 $25.4M +$5.58M +28.2% Sep 30, 2021 10-Q 2021-11-04
Q2 2021 $21M +$5.28M +33.6% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $17M +$2.16M +14.5% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $19.5M +$5.95M +43.8% Dec 31, 2020 10-K 2022-03-01
Q3 2020 $19.8M +$5.79M +41.3% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $15.7M +$2.08M +15.3% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $14.8M +$4.54M +44.1% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $13.6M +$4.46M +48.9% Dec 31, 2019 10-K 2021-03-01
Q3 2019 $14M +$4.68M +50.2% Sep 30, 2019 10-Q 2019-11-13
Q2 2019 $13.6M Jun 30, 2019 10-Q 2019-08-14
Q1 2019 $10.3M Mar 31, 2019 10-Q 2019-05-10
Q4 2018 $9.12M +$1.2M +15.1% Dec 31, 2018 10-K 2020-03-12
Q3 2018 $9.32M Sep 30, 2018 10-Q 2018-11-13
Q4 2017 $7.93M Dec 31, 2017 10-K 2019-03-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.